Fusen Pharmaceutical Company Limited announced that the application for launching Metformin Empagliflozin Tablets (I), developed by Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited, has been submitted to and accepted by the National Medical Products Administration of the People's Republic of China. The product is used for the treatment of the following diseases: in conjunction with diet control and exercise, it is suitable for adult patients with type 2 diabetes who are receiving treatment with Empagliflozin and Metformin Hydrochloride to improve the blood glucose control of such patients. Metformin Empagliflozin Tablets (I) is a compound preparation consisting of Metformin Hydrochloride and Empagliflozin.

Its pharmacological effects are as follows: Metformin reduces hepatic glucose production, inhibits intestinal absorption of glucose, and increases the uptake and utilization of glucose in peripheral tissues. It improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Empagliflozin is an SGLT2 inhibitor that reduces renal glucose reabsorption, lowers the renal glucose threshold, and promotes the excretion of glucose in the urine.

Both components have a synergistic effect in terms of mechanism and offer better hypoglycemic effect compared to ordinary single preparation.